Menlo Therapeutics
Latest round
- Series C
Last raised
- Jul 2017
Total raised
- $50M
Investors
- 9
About Menlo Therapeutics
Founded in 2003 and based in Redwood City, California, Vyne Therapeutics Inc.Vyne Therapeutics Inc. is engaged in the development of therapies targeting immuno-inflammatory conditions through proprietary platforms. The company was founded in 2003 in Redwood City, California.915 mn. The company has not been reported as a subsidiary nor has it undergone a merger.Vyne Therapeutics focuses on developing proprietary and innovative therapies aimed at treating immuno-inflammatory conditions. The company's core product offerings include the InhiBET™ BET Inhibitor Platform, along with specific drug candidates such as VYN201 and VYN202. These products are designed to address significant therapeutic challenges by targeting key biological pathways associated with various diseases. The end users of these therapies primarily include healthcare professionals, patients suffering from immuno-inflammatory disorders, and research institutions involved in drug development.Vyne Therapeutics generates revenue primarily through partnerships and collaborations with pharmaceutical companies and research institutions. In the most recent year of 2024, the company's revenue amounted to USD 501,000, with an EBITDA of USD -43,633,000. The pricing structures for these offerings are aligned with industry standards for therapeutic products, reflecting the value of Vyne's proprietary technologies and the potential impact on patient outcomes.Vyne Therapeutics aims to expand its product offerings and reach new markets. The company is actively designing new therapies targeting specific immuno-inflammatory conditions, although precise release dates have not been disclosed. Furthermore, Vyne is looking to expand into additional markets in Asia and Europe by the end of 2025. Additionally, it was reported that Novo Holdings, Rock Springs Capital, and other partners exited their stakes in Vyne Therapeutics, although financial terms were not disclosed.
Who invested in Menlo Therapeutics
9 investors across 1 round
See all investors in Menlo Therapeutics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series C
Jul 18, 2017
Amount
$50M
Investors
Questions about Menlo Therapeutics
Who invested in Menlo Therapeutics?
Menlo Therapeutics has 9 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Menlo Therapeutics raised?
Menlo Therapeutics has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did Menlo Therapeutics last raise money?
Menlo Therapeutics's most recent round on record is a Series C, in Jul 2017.
What does Menlo Therapeutics do?
Founded in 2003 and based in Redwood City, California, Vyne Therapeutics Inc.
Where is Menlo Therapeutics headquartered?
Menlo Therapeutics is headquartered in Redwood City, US.
Which VCs invest in companies like Menlo Therapeutics?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back pharmaceuticals companies at Menlo Therapeutics's stage. Their profiles are linked below.
VCs backing pharmaceuticals startups at Series C
Raising like Menlo Therapeutics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.